<DOC>
	<DOCNO>NCT00959582</DOCNO>
	<brief_summary>This study characterize FDG-PET ( 18F-Fluorodeoxyglucose-Positron Emission Tomography ) early response marker recurrent , platinum-sensitive ovarian cancer treat platinum-based therapy .</brief_summary>
	<brief_title>Positron Emission Tomography/Computed Tomography ( PET/CT ) Relapsed Ovarian Cancer ( MK-0000-143 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Patient ovarian , primary peritoneal , fallopian tube cancer Patient first subsequent relapse Patient least prior platinumbased treatment ovarian cancer Patient schedule receive treatment carboplatin cisplatin monotherapy combination one drug platinum Patient pregnant Patient abdominal surgery within last 6 week Patient life expectancy &lt; 6 month Patient radiotherapy abdomen pelvis within last 6 month Patient poorly control diabetes</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Relapsed ovarian cancer</keyword>
</DOC>